Personalis, Inc.
$6.34
▲
0.3%
2026-04-21 08:58:01
www.personalis.com
NGM: PSNL
Explore Personalis, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$663.37 M
Current Price
$6.34
52W High / Low
$11.5 / $3.09
Stock P/E
—
Book Value
$2.55
Dividend Yield
—
ROCE
-29.9%
ROE
-35.02%
Face Value
—
EPS
$-0.91
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
259
Beta
2.21
Debt / Equity
16.85
Current Ratio
6.76
Quick Ratio
6.63
Forward P/E
-6.45
Price / Sales
9.05
Enterprise Value
$433.94 M
EV / EBITDA
-5.56
EV / Revenue
6.23
Rating
None
Target Price
$11.43
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Inotiv, Inc. | $0.29 | — | $9.46 M | — | -17.26% | -49.76% | $3.32 / $0.22 | $3.17 |
| 2. | Qiagen N.V. | NOT FOUND | — | — | 0.64% | 9.02% | 11.57% | $57.81 / $38.8 | $18.33 |
| 3. | Exagen Inc. | $2.99 | — | $72.61 M | — | -32.08% | -1.48% | $12.23 / $2.59 | $0.76 |
| 4. | Myriad Genetics, Inc. | $5.14 | — | $484.84 M | — | -11.84% | -23.51% | $8.59 / $3.76 | $3.94 |
| 5. | ENDRA Life Sciences Inc. | $6.01 | — | $7.46 M | — | -281.17% | -2.92% | $11.96 / $2.9 | $0.22 |
| 6. | FONAR Corporation | $18.8 | 15.61 | $117.93 M | — | 5.81% | 6.01% | $18.86 / $12 | $27.01 |
| 7. | Precipio, Inc. | $28.15 | — | $50.21 M | — | -6.84% | -2.72% | $29.8 / $5.19 | $8.18 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 17.34 M | 14.49 M | 17.2 M | 20.61 M | 16.8 M | — |
| Operating Profit | -25.27 M | -23.29 M | -21.8 M | -17.7 M | -18.11 M | — |
| Net Profit | -23.81 M | -21.65 M | -20.06 M | -15.75 M | -16.43 M | — |
| EPS in Rs | -0.23 | -0.21 | -0.19 | -0.15 | -0.16 | -0.64 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 69.65 M | 84.61 M | 73.48 M | 65.05 M |
| Operating Profit | -88.06 M | -68.27 M | -96.29 M | -115.53 M |
| Net Profit | -81.27 M | -81.28 M | -108.3 M | -113.31 M |
| EPS in Rs | -0.78 | -0.78 | -1.03 | -1.08 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 334.16 M | 270.27 M | 225.1 M | 292.7 M |
| Total Liabilities | 72.98 M | 67.31 M | 95.66 M | 74.56 M |
| Equity | 261.19 M | 202.96 M | 129.44 M | 218.14 M |
| Current Assets | 267.95 M | 203.01 M | 146.74 M | 199.7 M |
| Current Liabilities | 39.63 M | 31.13 M | 47.23 M | 33.13 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -74.95 M | -45.15 M | -56.26 M | -70.23 M |
| Investing CF | -22.57 M | -35.07 M | 13.1 M | 52.54 M |
| Financing CF | 130.34 M | 114.67 M | 11.03 M | 1.37 M |
| Free CF | -79.45 M | -46.75 M | -67.17 M | -120.13 M |
| Capex | -4.5 M | -1.6 M | -10.91 M | -49.9 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 15.15% | 12.97% | — | — |
| Earnings Growth % | 24.94% | 4.43% | — | — |
| Profit Margin % | -96.06% | -147.38% | -174.2% | — |
| Operating Margin % | -80.68% | -131.05% | -177.61% | — |
| Gross Margin % | 31.7% | 24.78% | 20.52% | — |
| EBITDA Margin % | -83.08% | -131.74% | -160.87% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.